WE MADE THE HONOR ROLL
MLABS DELIVERS CONFIDENCE
MLabs is a full-service reference laboratory, with more than 30 years’ experience providing state-of-the-science tools and expertise to help clinicians and patients choose the right clinical path.
MLabs is part of Michigan Medicine – one of the largest hospital systems in the world, and one of the best – ranked #11 in the nation and #1 in the state by U.S. News and World Report.
MLabs’ hybrid model combines the scientific rigor and proactive infrastructure investment of a leading academic research institution with the efficiency, flexibility and responsiveness of a private reference lab.
MLabs connects pathologists, clinicians, health systems and commercial laboratories with the next-generation testing modalities and consultative support needed to meet the challenges of personalized, precision medicine.
MLabs offers the uncompromised credibility and integrity of Michigan Medicine’s Department of Pathology Laboratories at one of the nation’s top academic medical centers. For your convenience, we have posted all of our certifications and accreditations.
MLabs shares the institution's commitment to applying established quality principles to clinical laboratory testing. Like other large organizations in complex, consequential fields, we rely on an established approach to monitor quality throughout the testing process.
The majority of Michigan Medicine’s pathology enterprise – including MLabs, now occupies 146,000 square feet in five contiguous buildings of the North Campus Research Complex, located about 4.5 miles from the main hospital campus. The space, configured with lean facility design principles, is now home to 150+ faculty members and 700+ laboratory technicians and staff.
BEHIND OUR WORK
Meeting the needs of today’s patients by delivering the highest quality laboratory results in a cost-effective manner, offering:
- A complete menu of the laboratory tests that drive personalized medicine, including state-of-the-science molecular diagnostic and interpretive services
- Nationally-recognized faculty, easily accessible for consultation
- On-time delivery of effective, comprehensive reports
- Dedication to creating and supporting strategic pathology partnerships
Driving tomorrow’s health care solutions with state-of-the-science, personalized laboratory information and consultation.
OUR LEADERSHIP TEAM
Jeffrey Myers, M.D. is the A. James French Professor of Diagnostic Pathology and Vice Chair for Clinical Affairs and Quality at Michigan Medicine. Since 2011, he has served as MLabs’ Medical Director.
Dr. Myers studied medicine at the University of North Dakota School of Medicine before transferring to Washington University School of Medicine in St. Louis, where he earned his medical degree. Following a pathology fellowship and an academic appointment at the University of Alabama, Birmingham, he served for a decade as Division Chair in Anatomic Pathology at the Mayo Clinic.
Dr. Myers’ interest in surgical and thoracic pathology is matched by his strong commitment to quality, safety, service excellence and innovation. His current focus is understanding the value of working directly with patients and families to transform their experience of pathology services and extending that patient-centered care model to MLabs’ diverse portfolio of regional and national clients.
MLabs Associate Director Julia Dahl, M.D., is board certified in anatomic and clinical pathology with special expertise in immunohistochemistry, GI/liver and placental pathology. Dr. Dahl has lectured and authored numerous journal articles and book chapters on pathology and is a past treasurer and chair of the finance committee for the U.S. & Canadian Academy of Pathology.
Dr. Dahl was recruited to U-M in 2016 after fifteen years in private practice. Before joining MLabs, she focused on GI/liver pathology in high-volume specialty laboratories, founding Mosaic Pathology Consultants, a Memphis, TN-based provider of specialty and hospital-based pathology, in 2005. Mosaic turned to MLabs as a primary partner for consultation in flow cytometry and molecular diagnostics to help them serve a more diverse and complex patient base. Dr. Dahl is also Founder, C.E.O. and Medical Director of DxOptim, LLC, a manufacturer of quality control materials for immunohistochemistry, in situ hybridization and histochemical stain procedures.
As a physician leader, academician and entrepreneur, Dr. Dahl brings a unique perspective to the MLabs leadership team.
Deirdre Fidler provides strategic planning and managerial oversight for MLabs’ administrative and operational activities. She has spent 25 of her 32 years at the University of Michigan with MLabs, overseeing activities in contracting, billing and finance, client service, and operations.
Fidler’s 30+ year career with the University of Michigan began as a Medical Technologist. She joined MLabs in 1995 after earning a master’s degree in health service administration from the U-M School of Public Health.
Business Development Manager
Karla Bialk leads MLabs’ business development team, responsible for strategic planning and initiatives related to growing business volume and expanding our geographic reach.An accomplished healthcare executive with an impressive record of success, Karla is committed to inspiring teams, maximizing talent and championing continuous improvement.
Prior to joining MLabs, Karla served in various leadership roles at Ascension-Providence Health System (formerly St. John Health), including Business Development Director and Core Lab Director, after gaining significant hands-on experience, first as a medical technologist and then a client services representative, supervisor, specialist and manager.
NEWS & EVENTS
Join us in recognizing patient safety awareness week by reviewing our critical values policy. Download our flyer that shows the importance of critical values and how they can affect the lives of patients. And finally, if you are a client and looking for an instructional video for the critical values survey, please find that video link below.
U-M was recently ranked No. 9 among institutions globally in cancer research, according to the U.S. News & World Report 2021 Best Global University Rankings.
The detection of DDIT3 rearrangements can be useful in diagnosing myxoid liposarcoma – including uncommon histologic variants – and in distinguishing this sarcoma from other mesenchymal tumors that may be considered in the differential diagnosis.